Experimental Alzheimer's drug slows cognitive decline in trial, firms say - The Washington Post
Makers of the drug have already applied to the Food and Drug Administration for accelerated approval for lecanemab, based on earlier-stage data.
An experimental Alzheimers drug slowed cognitive and functional decline by 27 percent in a closely watched clinical trial, the sponsors of the medication said Tuesday, increasing the therapys chance … [+3698 chars]
Read More
Other Stories in Business
- Gulf War veteran executed for 1998 quadruple murder despite claims of mental illness
- Guardant Health (GH) Reports Strong Q1 2025 Revenue Growth
- Connecting Asia's startup ecosystem
- Connecting Asia's startup ecosystem
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- Business First Bancshares, Inc. (BFST) Q1 2025 Earnings Call Transcript
